MedTrace Logo

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

NCT00003243 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2010-03-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. White blood cells from donors may be able to kill cancer cells in patients who have hematologic cancer that has recurred following bone marrow transplantation.

PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus infusion of donated white blood cells in treating patients who have hematologic cancer that has recurred after bone marrow transplantation.

Conditions

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

filgrastim

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

cyclophosphamide

DRUG

etoposide

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Ephraim J. Fuchs, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003243 on ClinicalTrials.gov